Journal Article Summary
The article investigates the effects of semaglutide, a medication used for weight loss, on reproductive outcomes in women with overweight and obesity who are experiencing infertility. This topic is significant because infertility affects a considerable number of individuals, and obesity is a known factor that can complicate fertility. Understanding how medications that promote weight loss, like semaglutide, impact reproductive health is crucial for guiding treatment decisions and improving outcomes for women trying to conceive.
The study analyzed data from 1,936 women aged 20 to 40 who had infertility issues and had lost weight within a year before seeking fertility treatment. The researchers compared outcomes between women who had used semaglutide and those who had not, focusing on clinical pregnancy rates, live birth rates, and miscarriage rates. The findings revealed that women who used semaglutide had lower rates of pregnancy and live births across different body mass index (BMI) categories, particularly among those with class I obesity. While miscarriage rates did not differ significantly between the groups, the overall results suggest that semaglutide pretreatment may negatively affect reproductive outcomes.
The study has several limitations, including its retrospective design, which means it cannot establish cause-and-effect relationships. Additionally, important details about the timing and dosage of semaglutide use were not captured, which could influence the results. Patients considering semaglutide should discuss these findings with their healthcare providers, especially regarding the timing of medication discontinuation before attempting to conceive, as the FDA recommends stopping semaglutide at least two months prior to conception. This conversation is essential to ensure that women receive personalized care that considers both their weight management and reproductive health needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Wu Yen-Chen, Hsu Jason C., Su Emily Chia-Yu, Chen Chi-Huang, Chang Tzu-Hao. Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study. Reproductive Biology and Endocrinology : RB&E 2026. DOI: 10.1186/s12958-026-01549-6. PMID: 42001071. PMCID: PMC13224514.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 — 10 mg / 2 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
